Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Stifel starts Immunic at buy; PT $2.50

Stifel initiated coverage of Immunic (NASDAQ: IMUX) with a “buy” rating and price target of $2.50. The stock closed at $1.11 on April 15. Immunic is a biotechnology company developing vidofludimus calcium (VidoCa) for...

April 16, 2026

Markets

Rodman & Renshaw starts TuHURA at buy; PT $7

Rodman & Renshaw initiated coverage of TuHURA Biosciences (NASDAQ:HURA) with a “buy” rating and price target of $7.00. The stock closed at $3.15 on April 14th. TuHURA is currently undertaking a Phase 3 trial for its...

April 15, 2026

Markets

Piper starts Adagio at overweight; PT $3

Piper Sandler initiated coverage of Adagio Medical Holdings (NASDAQ: ADGM) with an “overweight” rating and price target of $3.00. The stock closed at $1.33 on April 13th. Adagio is a pre-commercial medtech company that...

April 14, 2026

Markets

Stifel starts Tectonic Therapeutic at buy; PT $75

Stifel initiated coverage of Tectonic Therapeutic (NASDAQ:TECX) with a “buy” rating and price target of $75.00. The stock closed at $29.96 on April 13. Tectonic is a clinical-stage biotech, developing therapies...

April 13, 2026

Markets

Clear Street upgrades Korro Bio to buy; PT to $18.00 from $10.00

Clear Street upgraded Korro Bio (NASDAQ: KRRO) to “buy” from “hold” and raised its price target to $18.00 from $10.00, following Korro’s late January Analyst Day detailing their new lead program, KRRO-121 for...

February 18, 2026

Markets

Lake Street sees CMS’s proposed 2026 TULSA reimbursement as favorable

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $11 target price on the company’s stock...

July 16, 2025

Markets

Light AI goes public on CBOE Canada, stock rallies on first day of trading

Light AI (CBOE CA: ALGO) announced the completion of its IPO (including the agents’ full exercise of their over-allotment option) and began trading on CBOE Canada today. Including the units sold pursuant to the over...

January 8, 2025

Markets

Lake Street analyst pitches Profound Medical as one of his ‘best ideas’ for 2025

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $17 target price on the company’s stock...

January 2, 2025

Markets

Clear Street initiates coverage of several healthcare stocks

Analysts Kaveri Pohlman, PhD and Bill Maughan, PhD from Clear Street, a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, have launched coverage of several healthcare names. “The...

December 11, 2024

Markets

Leede Financial starts Nanalysis Scientific at buy; PT C$0.90

Leede Financial launched coverage of Nanalysis Scientific (TSXV: NSCI) (OTCQX: NSCIF) with a “speculative buy” rating and C$0.90 target price. The stock closed at $0.365 on November 22. Nanalysis operates two distinct...

November 25, 2024

Markets

Capricor prices common stock offering

Capricor Therapeutics (NASDAQ:CAPR) has priced a public offering of 4,412,000 common shares at a price of $17.00 per share. Capricor also granted underwriters a 30-day option to purchase up to an additional 661,800...

October 17, 2024

Markets

BTIG starts Definitive Healthcare at buy; PT $7

BTIG launched coverage of Definitive Healthcare (NASDAQ:DH) with a “buy” rating and $7 target price. The stock closed at $4.44 on September 16. Definitive Healthcare is one of the industry’s most comprehensive...

September 18, 2024

Markets

Exicure announces reverse split to gain Nasdaq compliance

Exicure (NASDAQ:XCUR) has announced a 1-for-5 reverse stock split of its outstanding common shares. The reverse stock split is expected to become effective at 5:00 p.m. on August 27, 2024, with the common stock...

August 26, 2024

Markets

EF Hutton starts CytoSorbents at buy; PT $10

EF Hutton launched coverage of CytoSorbents (NASDAQ:CTSO) with a “buy” rating and $10 target price. The stock closed at $1.03 on July 26. CytoSorbents’ innovative filter cartridges, CytoSorb, and DrugSorb, stand...

July 29, 2024

Markets

Lake Street starts Profound Medical at Buy; PT $16.50

Lake Street initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $16.50 price target. The stock closed at $10.19 on July 22. Analyst Ben Haynor writes that with reimbursement of TULSA...

July 23, 2024

Markets

Stifel upgrades Profound Medical to buy on CMS reimbursement; PT to $12

After market close today, Stifel upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “buy” from “hold” and raised its price target to $12 from $9 in response to the U.S. Centers for Medicare and Medicaid Services (CMS)...

July 15, 2024

Markets

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

July 15, 2024

Markets

Raymond James upgrades Alpha Cognition to outperform; PT to $2

Raymond James upgraded Alpha Cognition (CSE:ACOG) to “outperform” from “market perform” and raised its price target to C$2 from C$1 with the company’s PDUFA date less than 2 weeks away (July 27th). The stock closed at...

July 15, 2024

Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

March 28, 2024

Markets

Sigyn announces reverse split to support uplist to Nasdaq

Sigyn Therapeutics (OTCQB:SIGY) announced a 1-for-40 reverse split. Sigyn’s common stock is expected to begin trading on a split-adjusted basis on OTCQB when the market opens on Jan. 31. As a result of the split...

January 30, 2024

Markets

Avenue Therapeutics Reaches Final Agreement with FDA for the Phase 3 Safety Study for IV Tramadol

Fortress Biotech (NASDAQ:FBIO) partner company, Avenue Therapeutics (NASDAQ:ATXI) announced that it reached a final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach...

January 4, 2024

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Subscribe